Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting

ConferenceFT819Positive

AI Analysis

Summary

Fate Therapeutics announced it will present preliminary clinical data for FT819, an off-the-shelf CAR T-cell product candidate, for systemic sclerosis at the ISSCR 2026 Annual Meeting.

Clinical Trial Data

Outcome Details

Preliminary clinical data presentation

Importance:5/10

Sentiment:

0.30

CAR-Toff-the-shelfsystemic sclerosisclinical dataconference presentation

Related Companies

$FATE

Read the original article

Published by yahoo_finance on July 6, 2026 12:30 PM

Read Original